Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ly2624803. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 7/20 | 0.70 |
| ▸ | HTR2C | P28335 | 9/20 | 0.73 |
| ▸ | HTR2A | P28223 | 12/20 | 0.72 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ly2624803 SCHEMBL31208381 | 1.00 | HTR2C (0.73) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194094 | 0.92 | HTR2A (0.87) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194103 | 0.91 | HTR2A (0.72) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194066 | 0.91 | HTR2C (0.76) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194052 | 0.91 | HTR2C (0.79) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194111 | 0.91 | HTR2A (0.89) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194079 | 0.90 | HTR2A (0.71) | HTR2CHTR2AHRH1DRD2 | |
| SCHEMBL10194082 | 0.90 | HTR2A (0.87) | HTR2CHTR2AHRH1 | |
| SCHEMBL10194069 | 0.90 | HTR2C (0.68) | HTR2CHTR2AHRH1 | |
| SCHEMBL10194060 | 0.90 | HTR2C (0.66) | HTR2CHTR2AHRH1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| EP-3630102-B1 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | GLYTECH LLC (US) | 2024-08-14 | — | — | EP | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| US-11969431-B2 | Formulations for treatment of post-traumatic stress disorder | GLYTECH LLC (US) | 2024-04-30 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2023107966-A1 | SALT AND SOLID FORMS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND ANALOGS | TERRAN BIOSCIENCES, INC. (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-4748392-A1 | VACCINE FORMULATION | MinervaX ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-122031506-A | Chiral control | 波涛生命科学有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7592333-B2 | Loxapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592333-B2 | Loxapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, HTR2C, TPH1 | HRH1 402/4885HTR2C 2/4885HTR2A 14/4885 |
| US-20260138985-A1 | Azepino-Indoles for the Treatment of Neurological and Psychiatric Disorders | TPH2, TPH1, HTR1D | HRH1 1240/4885HTR2C 4/4885HTR2A 5/4885 |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | OPRD1, CRH, HTR2C | HRH1 242/4885HTR2C 3/4885HTR2A 98/4885 |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HRH1 1408/4885HTR2C 5/4885HTR2A 37/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HRH1 575/4885HTR2C 5/4885HTR2A 2/4885 |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | HCRTR2, HCRTR1, HTR3B | HRH1 858/4885HTR2C 4/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.